| Assay ID | Title | Year | Journal | Article |
|---|
| AID1192621 | Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | | | |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | | | |
| AID1708793 | Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using p-tyramine as substrate incubated for 30 mins by Amplex red reagent based fluorescence analysis | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID718026 | Inhibition of human recombinant MAO-B expressed in insect cell microsome assessed as 4-hydroxyquinoline formation using kynuramine as substrate after 20 mins by fluorescence spectrophotometry | 2012 | Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24
| Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | | | |
| AID1571214 | Inhibition of MAOA (unknown origin) using kynuramine as substrate preincubated for 30 mins followed by substrate addition | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11
| Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | | | |
| AID1571216 | Selectivity index, ratio of IC50 for MAOA (unknown origin) to IC50 for MAOB (unknown origin) | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11
| Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | | | |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | | | |
| AID773445 | Reversible inhibition of recombinant human MAO-B assessed as inhibition of kynuramine conversion to fluorescent metabolite 4-hydroxyquinoline after 20 mins by fluorescence spectrophotometry | 2013 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
| Inhibition of monoamine oxidase by 3,4-dihydro-2(1H)-quinolinone derivatives. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | | | |
| AID1373684 | Inhibition of human recombinant MAOB assessed as residual enzyme activity at 2 time IC50 pre-incubated for 30 mins followed by 0.06 mM benzylamine substrate addition | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Selective inhibition of monoamine oxidase A by hispidol. |
| AID1571215 | Inhibition of MAOB (unknown origin) using benzylamine as substrate preincubated for 30 mins followed by substrate addition | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11
| Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. |
| AID1708806 | Cytotoxicity against human HepG2 cells assessed as cell viability at 30 uM incubated for 2 hrs by MTT assay relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1192633 | Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 100 uM after 20 mins by SYPRO orange staining-based fluorescence assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1413451 | Competitive inhibition of recombinant human MAO-A assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by Lineweaver-Burk plot analysis | | | |
| AID1708794 | Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using p-tyramine as substrate incubated for 30 mins by Amplex red reagent based fluorescence analysis | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | | | |
| AID1152188 | Inhibition of recombinant human MAO-A using kynuramine as substrate assessed as 4-hydroxyquinoline production after 30 mins by fluorescence spectrophotometry analysis | 2014 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
| α-Tetralone derivatives as inhibitors of monoamine oxidase. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | | | |
| AID254307 | Inhibition constant against human recombinant Monoamine oxidase-B | 2005 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
| Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. |
| AID125713 | In vitro inhibitory activity against rat brain Monoamine oxidase A | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
| Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. |
| AID1192622 | Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1409012 | Inhibition of recombinant human MAO-B using kynuramine as substrate after 20 mins by fluorescence spectrophotometric analysis | 2018 | Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
| Synthesis and evaluation of 2-substituted 4(3H)-quinazolinone thioether derivatives as monoamine oxidase inhibitors. |
| AID1432432 | Inhibition of recombinant human MAO-B using benzylamine as substrate preincubated for 30 mins followed by substrate addition | 2017 | Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
| Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone. |
| AID1278145 | Inhibition of recombinant human MAO-B after 20 mins using 50 uM kynuramine as substrate by fluorescence spectrophotometry | 2016 | Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
| Inhibition of monoamine oxidase by benzoxathiolone analogues. |
| AID1192630 | Reversible inhibition of MAO-B in rat whole brain homogenate assessed as recovered activity at 100 times IC50 incubated for 60 mins followed by 6 washes by Amplex Red assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1373685 | Reversible inhibition of human recombinant MAOB assessed as residual enzyme activity at 2 times IC50 pre-incubated with enzyme for 30 mins followed by dialysis with pH 7.2 sodium phosphate buffer for 6 hrs followed by 0.06 mM benzylamine substrate additio | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Selective inhibition of monoamine oxidase A by hispidol. |
| AID1708798 | Reversible inhibition of human MAO-B assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured before dialysis relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | | | |
| AID1413448 | Inhibition of recombinant human MAO-A assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by amplex red reagent based fluorescence assay | | | |
| AID751623 | Inhibition of human recombinant monoamine oxidase-B assessed as kynuramine conversion to 6-hydroxyquinoline after 20 mins by fluorescence spectrophotometric analysis | 2013 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
| Inhibition of monoamine oxidase by phthalide analogues. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | | | |
| AID1158611 | Inhibition of recombinant human MAO-B expressed in insect cells assessed as inhibition of oxidation of kynuramine to 4-hydroxyquinoline after 20 mins by fluorescence spectrophotometry | 2014 | European journal of medicinal chemistry, Jul-23, Volume: 82 | New insights into the biological properties of Crocus sativus L.: chemical modifications, human monoamine oxidases inhibition and molecular modeling studies. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | | | |
| AID1194962 | Inhibition of human recombinant MAOB using kynuramine substrate assessed as reduction in MAO-generated 4-hydroxyquinoline level by fluorescence spectrophotometry | 2015 | Bioorganic & medicinal chemistry letters, May-01, Volume: 25, Issue:9
| The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase. |
| AID1624337 | Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by spectrophotometric analysis | 2019 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
| Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity. |
| AID1297408 | Inhibition of human recombinant MAO-B using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometric analysis | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
| An evaluation of synthetic indole derivatives as inhibitors of monoamine oxidase. |
| AID1192164 | Inhibition of human recombinant MAO-B assessed as kynuramine oxidation to 4-hydroxyquinoline formation by spectrofluorometric analysis | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
| Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | | | |
| AID1192163 | Inhibition of human recombinant MAO-A assessed as kynuramine oxidation to 4-hydroxyquinoline formation by spectrofluorometric analysis | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
| Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives. |
| AID1708797 | Reversible inhibition of human MAO-A assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured before dialysis by dialysis method relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1192632 | Inhibition of human recombinant soluble MAO-B assessed as thermal shift after 20 mins by SYPRO orange staining-based fluorescence assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1571227 | Reversible inhibition of MAOB (unknown origin) assessed as residual enzyme activity at 0.08 uM using benzylamine as substrate measured after 30 mins relative to control | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11
| Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | | | |
| AID1399990 | Acute toxicity in po dosed rat | 2018 | Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
| Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase. |
| AID1413450 | Selectivity index, ratio of Ki for recombinant human MAO-B to Ki for recombinant human MAO-A | | | |
| AID1413449 | Inhibition of recombinant human MAO-B assessed as reduction in H2O2 production preincubated for 30 mins followed by p-tyramine substrate addition measured after 30 mins by amplex red reagent based fluorescence assay | | | |
| AID1708796 | Reversible inhibition of human MAO-A assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured 24 hrs post dialysis by dialysis method relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | | | |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | | | |
| AID1514581 | Inhibition of recombinant human MAOB expressed in insect cell microsomes using kynuramine as substrate measured after 20 mins by fluorescence spectrophotometry | 2019 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
| Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework. |
| AID1624340 | Competitive inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by Lineweaver-Burk plot analysis | 2019 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
| Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity. |
| AID1152189 | Inhibition of recombinant human MAO-B using kynuramine as substrate assessed as 4-hydroxyquinoline production after 30 mins by fluorescence spectrophotometry analysis | 2014 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
| α-Tetralone derivatives as inhibitors of monoamine oxidase. |
| AID1498690 | Inhibition of recombinant human MAO-B using benzylamine as substrate incubated for 30 mins by spectrophotometric method | 2018 | Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14
| Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid. |
| AID1192165 | Selectivity index, ratio of IC50 for human recombinant MAO-B to IC50 for human recombinant MAO-A | 2015 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6
| Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives. |
| AID1261174 | Inhibition of human MAO-B expressed in baculovirus infected BT1 cells microsome fraction by fluorescence spectrometry | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
| Monoamine oxidase inhibitory activities of heterocyclic chalcones. |
| AID1708799 | Reversible inhibition of human MAO-B assessed as residual enzyme activity at 4 fold IC50 incubated for 15 mins and measured 24 hrs post dialysis relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1896030 | Inhibition of MAO-B (unknown origin) | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
| The Repertoire of Small-Molecule PET Probes for Neuroinflammation Imaging: Challenges and Opportunities beyond TSPO. |
| AID1624338 | Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using benzylamine as substrate after 30 mins by spectrophotometric analysis | 2019 | Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
| Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity. |
| AID127198 | Inhibition of mitochondrial Monoamine oxidase-B purified from bovine liver | 1993 | Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
| New analogues of N-(2-aminoethyl)-4-chlorobenzamide (Ro 16-6491). Some of the most potent monoamine oxidase-B inactivators. |
| AID1708795 | Selectivity index, ratio of Ki for inhibition of recombinant human MAO-A to Ki for inhibition of recombinant human MAO-B using p-tyramine as substrate | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | | | |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | | | |
| AID1192631 | Binding affinity to human recombinant microsomal MAO-B by ITC | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1373672 | Inhibition of human recombinant MAOB using benzylamine as substrate preincubated for 30 mins followed by substrate addition | 2018 | Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
| Selective inhibition of monoamine oxidase A by hispidol. |
| AID1571228 | Reversible inhibition of MAOB (unknown origin) assessed as residual enzyme activity at 0.08 uM using benzylamine as substrate pre-incubated for 30 mins followed by dialysis with pH 7.2 sodium phosphate buffer relative to control | 2018 | MedChemComm, Nov-01, Volume: 9, Issue:11
| Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors. |
| AID234092 | Selectivity for the B form was estimated by the IC50(MAO A)/IC50(MAO B) ratio | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
| Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. |
| AID1484647 | Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cell microsomes using kynuramine as substrate after 20 mins by fluorescence spectroscopy | 2017 | European journal of medicinal chemistry, Jul-28, Volume: 135 | The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase. |
| AID1708805 | Cytotoxicity against human HepG2 cells assessed as cell viability at 15 uM incubated for 2 hrs by MTT assay relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID1413453 | Reversible inhibition of recombinant human MAO-A assessed as enzyme activity recovery at 5 time Ki value preincubated for 15 mins followed by dilution of enzyme-inhibitor mixture for 24 hrs and subsequent p-tyramine substrate addition by dialysis method | | | |
| AID1512063 | Inhibition of human recombinant MAO-B expressed in insect cells microsomes assessed as inhibition of 4-hydroxyquinoline formation using kynuramine as substrate incubated for 20 mins by fluorescence spectrophotometry analysis | 2019 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 29, Issue:21
| 1,3,4-Oxadiazol-2-ylbenzenesulfonamides as privileged structures for the inhibition of monoamine oxidase B. |
| AID126695 | In vitro inhibitory activity against rat brain Monoamine oxidase B | 1995 | Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24
| Selective and potent monoamine oxidase type B inhibitors: 2-substituted 5-aryltetrazole derivatives. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | | | |
| AID1192629 | Reversible inhibition of MAO-B in rat whole brain homogenate assessed as recovered activity at 100 times IC50 incubated for 60 mins followed by 3 washes by Amplex Red assay | 2015 | Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
| Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. |
| AID1708804 | Cytotoxicity against human HepG2 cells assessed as cell viability at 7.5 uM incubated for 2 hrs by MTT assay relative to control | 2021 | Journal of medicinal chemistry, 02-25, Volume: 64, Issue:4
| New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1345977 | Human Monoamine oxidase B (Catecholamine turnover) | 2005 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
| Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. |
| AID1345977 | Human Monoamine oxidase B (Catecholamine turnover) | 1990 | Advances in neurology, , Volume: 53 | Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |